New research released on Wednesday suggests that Ozempic and similar medications may have unexpected side effects. Doctors in Massachusetts have found a link between the drug’s active ingredient semaglutide and a higher risk of a rare condition that can cause blindness called nonarteritic anterior ischemic optic…
The future of weight loss is fast approaching. At a recent scientific conference, drug companies showed off a variety of next-generation drugs for both obesity and type 2 diabetes. Some of these treatments might help people lose even more weight than current forerunners like Novo Nordisk’s semaglutide—the active…
The World Health Organization is warning the public to stay away from counterfeit Ozempic, or “fauxzempic.” The agency has recently received reports of medication falsified to appear like the diabetes and off-label weight loss drug Ozempic in at least three countries, including the U.S.
It’s hard to go a day without hearing something new about the latest diabetes and obesity medications, semaglutide and tirzepatide. Usually, the buzz is positive, but there has been a persistent claim made about these drugs that would make any potential user wary: They don’t only help you lose weight—they supposedly…
New research this month is the latest to link the use of Ozempic, Wegovy, and other GLP-1 drugs to a greater risk of gastroparesis, a potentially serious medical condition. So what exactly is gastroparesis and how worried should you be about it if you’re on or thinking about taking these medications?
The millennial-skewed telehealth platform Hims & Hers announced Monday that is now offering customers a compounded version of semaglutide, the active ingredient in popular weight loss drugs like Ozempic and Wegovy.
Results from the longest-running trial of semaglutide—the active ingredient in the popular drugs Ozempic and Wegovy—are in, and the verdict is decidedly positive. The study found that people taking semaglutide tended to maintain their initial weight loss for up to four years. Other trial data presented this week also…
At least 224 people have been injured after an iPhone app called t:connect drained the battery on its accompanying insulin pump, called t:slim X2, causing the pump to fail to deliver insulin. The FDA issued a Class I recall of the app on Wednesday, according to a press release, the most serious type of recall issued…
The future of weight loss is looking more varied by the second. This week, scientists have reported the preliminary findings of a small trial testing out a novel, non-surgical procedure for obesity—one that works by burning part of the mucus-filled lining of the stomach. The patients in the trial lost about 8% of…